Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism

Modulation of nucleus accumbens connectivity by alcohol drinking and naltrexone in alcohol-preferring rats: A manganese-enhanced magnetic resonance imaging study

(2016) Mateusz Dudek et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals

(2015) Dennis D. Rasmussen et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse

(2015) Janice C. Froehlich et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Varenicline-induced acute liver injury with jaundice

(2015) Helga Mogensen et al.   HEPATOLOGY

Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis

(2015) K. H. Thomas et al.   BMJ-British Medical Journal

Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis

(2015) K. H. Thomas et al.   BMJ-British Medical Journal

Combining theα1-Adrenergic Receptor Antagonist, Prazosin, with theβ-Adrenergic Receptor Antagonist, Propranolol, Reduces Alcohol Drinking More Effectively Than Either Drug Alone

(2014) Dennis D. Rasmussen et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings

(2014) Lara A. Ray et al.   PSYCHOPHARMACOLOGY

Prazosin Reduces Alcohol Drinking Throughout Prolonged Treatment and Blocks the Initiation of Drinking in Rats Selectively Bred for High Alcohol Intake

(2013) Janice C. Froehlich et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Neuronal Nicotinic Acetylcholine Receptors: Common Molecular Substrates of Nicotine and Alcohol Dependence

(2013) Linzy M. Hendrickson et al.   Frontiers in Psychiatry

Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

(2012) Natalya C. Maisel et al.   ADDICTION

Naltrexone for the Treatment of Alcoholism: Clinical Findings, Mechanisms of Action, and Pharmacogenetics

(2012) Lara Ray et al.   CNS & Neurological Disorders-Drug Targets

Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats

(2011) Jade J. Bito-Onon et al.   ADDICTION BIOLOGY

A preliminary investigation of varenicline for heavy drinking smokers

(2011) Lisa M. Fucito et al.   PSYCHOPHARMACOLOGY

Partial Agonists of the α3β4* Neuronal Nicotinic Acetylcholine Receptor Reduce Ethanol Consumption and Seeking in Rats

(2010) Susmita Chatterjee et al.   NEUROPSYCHOPHARMACOLOGY

Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers

(2009) Sherry A. McKee et al.   BIOLOGICAL PSYCHIATRY

The Smoking Cessation Medication Varenicline Attenuates Alcohol and Nicotine Interactions in the Rat Mesolimbic Dopamine System

(2009) M. Ericson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats

(2009) Eoin C. O’Connor et al.   PSYCHOPHARMACOLOGY

The α1-Adrenergic Receptor Antagonist, Prazosin, Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats

(2008) Dennis D. Rasmussen et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH